Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin in relapsed/refractory multiple myeloma with hepatic impairment
NCT04398680Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Apr 2021
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of belantamab mafodotin in multiple myeloma (MM) (3 arms), sponsored by GSK. Primary endpoints: Maximum Observed Plasma Concentration of Belantamab Mafodotin at 48 months, Time to Maximum Concentration of Belantamab Mafodotin at 48 months and 15 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04398680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398680.